AstraZeneca Secures EU Approval for Datroway in First-Line Triple-Negative Breast Cancer
The antibody drug conjugate becomes the only TROP2-directed therapy approved in Europe with demonstrated overall survival benefit for metastatic TNBC patients ineligible for immunotherapy.
EU Commission Grants Approval for Second Indication
AstraZeneca PLC and partner Daiichi Sankyo announced European Union approval of Datroway (datopotamab deruxtecan) as monotherapy for first-line treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy, according to a 6-K filing dated July 31, 2026.
The approval follows a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency and marks Datroway's second breast cancer indication in the EU (6-K filing, 2026-07-31).
Clinical Trial Demonstrates Dual Endpoint Success
The European Commission's decision was based on results from the TROPION-Breast02 Phase III trial, which enrolled 644 patients across sites in Africa, Asia, Europe, North America and South America (6-K filing, 2026-07-31). The trial evaluated Datroway against investigator's choice of chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic TNBC.
The study met both dual primary endpoints, demonstrating "a statistically significant and clinically meaningful improvement" for overall survival and progression-free survival as assessed by blinded independent central review (6-K filing, 2026-07-31). Results were presented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology.
Datroway received a score of 4 out of 5 on the ESMO Magnitude of Clinical Benefit Scale and has been included in ESMO Clinical Practice Guidelines as a Category IA first-line treatment option for patients with metastatic TNBC who are not candidates for immunotherapy (6-K filing, 2026-07-31).
Addressing Significant Unmet Need
TNBC accounts for approximately 15% of all breast cancer cases, with an estimated 81,000 diagnoses in Europe annually (6-K filing, 2026-07-31). The disease is characterized by its aggressive nature and poor prognosis, with median overall survival of just 12 to 18 months and only about 15% of patients living five years following diagnosis (6-K filing, 2026-07-31).
Dave Fredrickson, Executive Vice President of AstraZeneca's Oncology Haematology Business Unit, stated: "Every year, more than 80,000 people in Europe are diagnosed with triple-negative breast cancer, a disease that often affects younger women and has limited treatment options in the metastatic setting" (6-K filing, 2026-07-31).
Approximately 70% of patients with metastatic TNBC are not candidates for immunotherapy, leaving chemotherapy as the previous standard first-line treatment (6-K filing, 2026-07-31).
Regulatory Status and Commercial Footprint
Datroway received US approval for the same indication in May 2026, with additional reviews underway in China, Japan, Australia, Canada, Singapore and Switzerland as part of Project Orbis (6-K filing, 2026-07-31).
The TROP2-directed antibody drug conjugate is now approved in more than 45 countries worldwide for HR-positive, HER2-negative breast cancer and in more than 30 countries for metastatic TNBC (6-K filing, 2026-07-31). A comprehensive global clinical development program includes more than 20 trials evaluating Datroway across multiple cancers.
MarginX data shows AstraZeneca's market capitalization stands at approximately $264 billion, with shares last closing at $126.32. The company is scheduled to present at the Ai4 2026 conference on August 4.
This article was generated by MarginX from the 6-K filing on 2026-07-31. It is not investment advice.